Future frontiers in the treatment of myelodysplastic syndromes.
Myelodysplastic syndromes (MDS), a group of bone marrow disorders characterized by the production of abnormally functioning, immature blood cells, are most prevalent in patients over 60 years of age. Supportive care has long been the mainstay of treatment; however, new clinical research shows promise for the treatment of MDS. This program focused on the pathophysiology of MDS, novel therapies for MDS, and key nursing considerations for treating these patients.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D005544:Forecasting; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000639:trends*; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000453:epidemiology / Q000628:therapy*; D024802:Nurse's Role; D009730:Nursing Assessment / Q000379:methods; D009859:Oncology Nursing / Q000379:methods / Q000639:trends*; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A